An eruption of basal cell carcinoma after ibrutinib

Ibrutinib is a therapy targeting tyrosine kinase that has been used for various hematologic malignancies. It is associated with a variety of adverse effects, several of which are dermatologic. While there are few discussions of basal cell carcinoma as an adverse event, there have not yet been report...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings (Baylor University. Medical Center) 2024, Vol.37 (2), p.334-335
Main Authors: Pan, Sharon, Housewright, Chad
Format: Report
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ibrutinib is a therapy targeting tyrosine kinase that has been used for various hematologic malignancies. It is associated with a variety of adverse effects, several of which are dermatologic. While there are few discussions of basal cell carcinoma as an adverse event, there have not yet been reports of a significantly increased incidence. Here, we present a patient with no dermatologic history who subsequently developed nearly 30 incidents of basal cell carcinoma after starting ibrutinib, leading to discontinuation of the therapy.
ISSN:0899-8280
DOI:10.1080/08998280.2023.2288482